Develops immunotherapies for cancer treatment, focusing on personalized medicine and targeting tumor-specific antigens.
Sensei Biotherapeutics, Inc. is a pioneering biopharmaceutical firm dedicated to advancing immunotherapy treatments, particularly focusing on cancer therapies. The company distinguishes itself through its innovative platforms: the ImmunoPhage platform utilizes bacteriophage to provoke a coordinated immune response, while the Tumor Microenvironment Activated Biologics platform aims to enhance T-cell anti-tumor capabilities. Sensei Biotherapeutics also develops human monoclonal antibodies tailored to activate within the tumor microenvironment, targeting immune checkpoints and critical pathways.
Among its promising pipeline, Sensei Biotherapeutics is progressing SNS-101, a monoclonal antibody designed for cancer treatment, and SNS-401-NG, an ImmunoPhage vaccine addressing multiple tumor antigens. The company's strategic collaboration with The University of Washington focuses on advancing research into a vaccine for Merkel cell carcinoma, underscoring its commitment to developing effective terapies for challenging cancers.
Originally founded as Panacea Pharmaceuticals, Inc. and rebranded as Sensei Biotherapeutics, Inc., the company has been at the forefront of immunotherapy innovation since its establishment in 1999. Headquartered in Boston, Massachusetts, Sensei Biotherapeutics continues to drive breakthroughs in cancer treatment, leveraging cutting-edge science and strategic partnerships to transform the landscape of oncology therapies.